SARS-CoV-2 vaccination efficacy on hospitalisation and variants.
作者信息
Rozencwajg Sacha, Blet Alice, Lamer Antoine, Boisson Matthieu, Clavier Thomas, Abou-Arab Osama
机构信息
AP-HP, Bichat University Hospital, DMU PARABOL, Department of Anaesthesiology and Critical Care, Paris, France.
AP-HP, Lariboisière-Saint-Louis Hospitals, Department of Anaesthesiology, Critical Care and Burn Centre, Paris, France; University of Paris, Inserm UMR-S 942, Cardiovascular Markers in Stress Conditions (MASCOT), Paris, France; University of Ottawa Heart Institute, University of Ottawa, Ottawa, Ontario, Canada.
出版信息
Anaesth Crit Care Pain Med. 2021 Apr 23:100867. doi: 10.1016/j.accpm.2021.100867.
Abstract
摘要
相似文献
1
SARS-CoV-2 vaccination efficacy on hospitalisation and variants.严重急性呼吸综合征冠状病毒2型疫苗对住院治疗及病毒变体的有效性
Anaesth Crit Care Pain Med. 2021 Apr 23:100867. doi: 10.1016/j.accpm.2021.100867.
2
Effectiveness of primary series and booster vaccination against SARS-CoV-2 infection and hospitalisation among adolescents aged 12-17 years in Singapore: a national cohort study.新加坡 12-17 岁青少年中针对 SARS-CoV-2 感染和住院的基础系列和加强针接种的有效性：一项全国队列研究。
Lancet Infect Dis. 2023 Feb;23(2):177-182. doi: 10.1016/S1473-3099(22)00573-4. Epub 2022 Sep 28.
3
Replacement dynamics and the pathogenesis of the Alpha, Delta and Omicron variants of SARS-CoV-2.SARS-CoV-2 的 Alpha、Delta 和奥密克戎变异株的替代动力学和发病机制。
Epidemiol Infect. 2022 Dec 20;151:e32. doi: 10.1017/S0950268822001935.
4
Effectiveness and durability of BNT162b2 vaccine against hospital and emergency department admissions due to SARS-CoV-2 omicron sub-lineages BA.1 and BA.2 in a large health system in the USA: a test-negative, case-control study.辉瑞-BioNTech 疫苗对美国大型医疗体系内因 SARS-CoV-2 奥密克戎 BA.1 和 BA.2 亚系导致的住院和急诊科就诊的有效性和持久性：一项病例对照研究
Lancet Respir Med. 2023 Feb;11(2):176-187. doi: 10.1016/S2213-2600(22)00354-X. Epub 2022 Oct 7.
5
SARS-CoV-2 in dialysis patients and the impact of vaccination.透析患者中的 SARS-CoV-2 与疫苗接种的影响。
BMC Nephrol. 2022 Sep 21;23(1):317. doi: 10.1186/s12882-022-02940-2.
6
The effectiveness of vaccination for preventing hospitalisation with COVID-19 in regional Queensland: a data linkage study.昆士兰州偏远地区接种疫苗对预防 COVID-19 住院的有效性：一项数据链接研究。
Med J Aust. 2023 Aug 21;219(4):162-165. doi: 10.5694/mja2.52019. Epub 2023 Jul 3.
7
EuCARE-hospitalised study protocol: a cohort study of patients hospitalised with COVID-19 in the EuCARE project.EuCARE-住院研究方案：EuCARE 项目中因 COVID-19 住院的患者的队列研究。
BMC Infect Dis. 2023 Oct 16;23(1):690. doi: 10.1186/s12879-023-08658-2.
8
First SARS-CoV-2 vaccine booster and influenza vaccination: risk assessment of COVID-19 hospitalisation and death.首剂 SARS-CoV-2 疫苗加强针和流感疫苗接种：COVID-19 住院和死亡的风险评估。
Epidemiol Prev. 2022 Sep-Dec;46(5-6):324-332. doi: 10.19191/EP22.5-6.070.
9
Clinical efficacy of anti-SARS-CoV-2 monoclonal antibodies in preventing hospitalisation and mortality among patients infected with Omicron variants: A systematic review and meta-analysis.抗SARS-CoV-2单克隆抗体预防感染奥密克戎变异株患者住院和死亡的临床疗效：一项系统评价和荟萃分析
Rev Med Virol. 2023 Jul;33(4):e2439. doi: 10.1002/rmv.2439. Epub 2023 Mar 16.
10
Increased risk of hospitalisation and intensive care admission associated with reported cases of SARS-CoV-2 variants B.1.1.7 and B.1.351 in Norway, December 2020 -May 2021.2020 年 12 月至 2021 年 5 月期间，在挪威报告的 SARS-CoV-2 变异株 B.1.1.7 和 B.1.351 与住院和重症监护入院风险增加相关。
PLoS One. 2021 Oct 11;16(10):e0258513. doi: 10.1371/journal.pone.0258513. eCollection 2021.
本文引用的文献
1
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.多种严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变体可逃避疫苗诱导的体液免疫的中和作用。
Cell. 2021 Apr 29;184(9):2523. doi: 10.1016/j.cell.2021.04.006.
2
Immunity to SARS-CoV-2: Lessons Learned.对 SARS-CoV-2 的免疫力：经验教训。
Front Immunol. 2021 Mar 19;12:654165. doi: 10.3389/fimmu.2021.654165. eCollection 2021.
3
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.腺病毒载体新冠疫苗（AZD1222）对 202012/01 关注变异株（B.1.1.7）的疗效：一项随机对照试验的探索性分析。
Lancet. 2021 Apr 10;397(10282):1351-1362. doi: 10.1016/S0140-6736(21)00628-0. Epub 2021 Mar 30.
4
Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant.感染和疫苗诱导的针对 B.1.351 SARS-CoV-2 变体的抗体结合和中和作用。
Cell Host Microbe. 2021 Apr 14;29(4):516-521.e3. doi: 10.1016/j.chom.2021.03.009. Epub 2021 Mar 20.
5
SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies.SARS-CoV-2 变体 B.1.351 和 P.1 逃避中和抗体。
Cell. 2021 Apr 29;184(9):2384-2393.e12. doi: 10.1016/j.cell.2021.03.036. Epub 2021 Mar 20.
6
COVID-19 vaccines: A race against time.新冠疫苗：与时间赛跑
Anaesth Crit Care Pain Med. 2021 Apr;40(2):100848. doi: 10.1016/j.accpm.2021.100848. Epub 2021 Mar 24.
7
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera.SARS-CoV-2 变体 B.1.351 从自然和疫苗诱导的血清中逃逸的证据。
Cell. 2021 Apr 29;184(9):2348-2361.e6. doi: 10.1016/j.cell.2021.02.037. Epub 2021 Feb 23.
8
Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera.BNT162b2 疫苗诱导的人血清对 SARS-CoV-2 谱系 B.1.1.7 假病毒的中和作用。
Science. 2021 Mar 12;371(6534):1152-1153. doi: 10.1126/science.abg6105. Epub 2021 Jan 29.
Zotero 插件